Missed opportunities for hepatitis C testing in opioid treatment programs.
Where this comes from
- Record sourced from PubMed, PMID 23597374.
- Also identified by DOI 10.2105/AJPH.2012.301129 and PMC identifier 3670662.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HCV has surpassed HIV as a cause of death in the United States and is particularly prevalent among injection drug users. I examined the availability of on-site HCV testing in a nationally representative sample of opioid treatment programs. Nearly 68% of these programs had the staff required for HCV testing, but only 34% offered on-site testing. Availability of on-site testing increased only slightly with the proportion of injection drug users among clients. The limited HCV testing services in opioid treatment programs is a key challenge to reducing HCV in the US population.
Medical subject headings
- Analgesics, Opioid
- Health Services Accessibility
- Hepatitis C
- Substance Abuse Treatment Centers
- Substance Abuse, Intravenous